Biofrontera AG reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was EUR 25.74 million compared to EUR 28.79 million a year ago. Net loss was EUR 44.17 million compared to net income of EUR 38.32 million a year ago.

Basic loss per share from continuing operations was EUR 0.77 compared to basic earnings per share from continuing operations of EUR 0.69 a year ago. Diluted loss per share from continuing operations was EUR 0.77 compared to diluted earnings per share from continuing operations of EUR 0.68 a year ago.